1 |
American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2008;31(Suppl 1):S55-60.
DOI
|
2 |
Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69.
DOI
|
3 |
Moolgavkar SH, Day NE, Stevens RG. Two-stage model for carcinogenesis: Epidemiology of breast cancer in females. J Natl Cancer Inst 1980;65:559-69.
|
4 |
Colditz GA, Rosner B. Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. Am J Epidemiol 2000;152:950-64.
DOI
|
5 |
Eliassen AH, Colditz GA, Rosner B, et al. Adult weight change and risk of postmenopausal breast cancer. JAMA 2006;296:193-201.
DOI
|
6 |
Boyd NF, Guo H, Martin LJ, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med 2007;356:227-36.
DOI
|
7 |
Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007;25:1329-33.
DOI
|
8 |
Resta F, Triggiani V, Sabba C, et al. The impact of body mass index and type 2 diabetes on breast cancer: current therapeutic measures of prevention. Curr Drug Targets Immune Endocr Metabol Disord 2004;4: 327-33.
DOI
|
9 |
Key TJ, Verkasalo PK, Banks E. Epidemiology of breast cancer. Lancet Oncol 2001;2:133-40.
DOI
|
10 |
Baron JA, Weiderpass E, Newcomb PA, et al. Metabolic disorders and breast cancer risk (United States). Cancer Causes Control 2001;12:875-80.
DOI
|
11 |
Lipscombe LL, Goodwin PJ, Zinman B, et al. Increased prevalence of prior breast cancer in women with newly diagnosed diabetes. Breast Cancer Res Treat 2006;98:303-9.
DOI
|
12 |
Arcidiacono B, Iiritano S, Nocera A, et al. Insulin resistance and cancer risk: an overview of the pathogenetic mechanisms. Exp Diabetes Res 2012;2012:789174.
|
13 |
Zakikhani M, Dowling R, Fantus IG, et al. Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 2006;66:10269-73.
DOI
|
14 |
Hundal RS, Krssak M, Dufour S, et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 2000;49:2063-9.
DOI
|
15 |
Lee JH, Kim TI, Jeon SM, et al. The effects of metformin on the survival of colorectal cancer patients with diabetes mellitus. Int J Cancer 2012;131:752-9.
DOI
|
16 |
Kourelis TV, Siegel RD. Metformin and cancer: new applications for an old drug. Med Oncol 2012;29:1314-27.
DOI
|
17 |
Bodmer M, Becker C, Meier C, et al. Use of metformin is not associated with a decreased risk of colorectal cancer: a case-control analysis. Cancer Epidemiol Biomarkers Prev 2012;21:280-6.
DOI
|
18 |
Ladson G, Dodson WC, Sweet SD, et al. The effects of metformin with lifestyle therapy in polycystic ovary syndrome: a randomized doubleblind study. Fertil Steril 2011;95:1059-66.
DOI
|
19 |
Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analysis. Ottawa Health Research Institute. http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm (Accessed on Aug 25, 2014).
|
20 |
Zheng JS, Hu XJ, Zhao YM, et al. Intake of fish and marine n-3 polyunsaturated fatty acids and risk of breast cancer: meta-analysis of data from 21 independent prospective cohort studies. BMJ 2013;346:f3706.
DOI
|
21 |
Libby G, Donnelly LA, Donnan PT, et al. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 2009;32:1620-5.
DOI
|
22 |
Bodmer M, Meier C, Krahenbuhl S, Jick SS, et al. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 2010;33:1304-8.
DOI
|
23 |
Bosco JL, Antonsen S, Sorensen HT, et al. Metformin and incident breast cancer among diabetic women: a population-based case-control study in Denmark. Cancer Epidemiol Biomarkers Prev 2011;20:101-11.
DOI
|
24 |
Ruiter R, Visser LE, van Herk-Sukel MP, et al. Lower risk of cancer in patients on metformin in comparison with those on sulfonylurea derivatives: results from a large population-based follow-up study. Diabetes Care 2012;35:119-24.
DOI
|
25 |
Bayraktar S, Hernadez-Aya LF, Lei X, et al. Effect of metformin on survival outcomes in diabetic patients with triple receptor-negative breast cancer. Cancer 2012;118:1202-11.
DOI
|
26 |
Hsieh MC, Lee TC, Cheng SM, et al. The influence of type 2 diabetes and glucose-lowering therapies on cancer risk in the Taiwanese. Exp Diabetes Res 2012;2012:413782.
|
27 |
Qiu H, Rhoads GG, Berlin JA, et al. Initial metformin or sulphonylurea exposure and cancer occurrence among patients with type 2 diabetes mellitus. Diabetes Obes Metab 2013;15:349-57.
DOI
|
28 |
Tseng CH. Metformin may reduce breast cancer risk in Taiwanese women with type 2 diabetes. Breast Cancer Res Treat 2014;145:785-90.
DOI
|
29 |
Redaniel MT, Jeffreys M, May MT, et al. Associations of type 2 diabetes and diabetes treatment with breast cancer risk and mortality: a population-based cohort study among British women. Cancer Causes Control 2012;23:1785-95.
DOI
|
30 |
Tsilidis KK, Capothanassi D, Allen NE, et al. Metformin Does Not Affect Cancer Risk: A Cohort Study in the U.K. Clinical Practice Research Datalink Analyzed Like an Intention-to-Treat Trial. Diabetes Care 2014;37:2522-32.
DOI
|
31 |
Lega IC, Austin PC, Gruneir A, et al. Association between metformin therapy and mortality after breast cancer: a population-based study. Diabetes Care 2013;36:3018-26.
DOI
|
32 |
Hou G, Zhang S, Zhang X, et al. Use of metformin and survival of diabetic women with breast cancer. Curr Drug Saf 2013;8:357-63.
DOI
|
33 |
Green AS, Chapuis N, Lacombe C, et al. LKB1/AMPK/mTOR signaling pathway in hematological malignancies: from metabolism to cancer cell biology. Cell Cycle 2011;10(13):2115-20.
DOI
|
34 |
Goodwin PJ, Stambolic V. Obesity and insulin resistance in breast cancer--chemoprevention strategies with a focus on metformin. Breast 2011;20(Suppl 3):S31-5.
|
35 |
Col NF, Ochs L, Springmann V, et al. Metformin and breast cancer risk: a meta-analysis and critical literature review. Breast Cancer Res Treat 2012;135(3):639-46.
DOI
|
36 |
Currie CJ, Poole CD, Gale EA. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009;52(9):1766-77.
DOI
|
37 |
Stevens RJ, Ali R, Bankhead CR, et al. Cancer outcomes and all-cause mortality in adults allocated to metformin: systematic review and collaborative meta-analysis of randomised clinical trials. Diabetologia 2012;55(10):2593-603.
DOI
|
38 |
Col NF, Ochs L, Springmann V, et al. Glucose lowering agents and the patterns of risk for cancer: a study with the General Practice Research Database and secondary care data. Diabetologia 2012;55(3):654-65.
DOI
|
39 |
Staa Van, Patel D, Gallagher AM, de Bruin ML. Diabetes, metformin, and breast cancer in postmenopausal women. J Clin Oncol 2012; 30:2844-52.
DOI
|
40 |
DeCensi A, Puntoni M, Goodwin P, et al. Metformin and cancer risk in diabetic patients: a systematic review and meta-analysis. Cancer Prev Res (Phila) 2010;3(11):1451-61.
DOI
|
41 |
Noto H, Goto A, Tsujimoto T, Noda M. Cancer risk in diabetic patients treated with metformin: a systematic review and meta-analysis. PLoS One 2012;7(3):e33411.
DOI
|
42 |
Bowker SL, Majumdar SR, Veugelers P, et al. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 2006;29(2):254-8.
DOI
|
43 |
Landman GW, Kleefstra N, van Hateren KJ, et al. Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 2010;33(2):322-6.
DOI
|
44 |
UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352(9131):854-65.
DOI
|
45 |
Mellbin LG, Malmberg K, Norhammar A, et al. Prognostic implications of glucose-lowering treatment in patients with acute myocardial infarction and diabetes: experiences from an extended follow-up of the Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) 2 Study. Diabetologia 2011;54(6):1308-17.
DOI
|